Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes ...

Researchers are applying insights into the genetic variations and physiology of obesity to apply tailored interventions to ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the ...

Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. Click here to read ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...